Risk factor
High price volatility
Profitability factor
Very low or no dividends
About
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devices for ischemic stroke thrombectomy, intracranial stenosis intervention, ischemic stroke prevention, hemorrhagic stroke treatment, and vascular access. These medical technologies are utilized for both the prevention and treatment of ischemic stroke, including acute ischemic events and intracranial narrowing, as well as for addressing hemorrhagic stroke. Established in 2016 and previously operating as Shanghai Care Medical Technology Corporation Limited, the company maintains its headquarters in Shanghai, People's Republic of China.
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral o
Target Price
The average target price of 6609.HK is 21.2 and suggests 60.3% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation t